Alliance Study result Summaries

The Alliance for Clinical Trials in Oncology strives to provide result summaries of its studies in an easy to read, understand, and use format. These summaries highlight recently published Alliance studies and contain resources for more information. To find result summaries, click on "type of cancer" or "condition" below.

THANK YOU to everyone who has participated in these clinical trials.
YOUR contributions will help new patients who are diagnosed with cancer.

Type of cancer

  • Breast Cancer
    • ACOSOG Z1071 Study that evaluated the role of sentinel lymph node dissection (SLND) surgery and axillary lymph node dissection (ALND) surgery after chemotherapy in patients with breast cancer that has spread to the lymph nodes in the breast area
    • ACOSOG Z1072* Study that looked at developing a new non-surgical treatment technique for adults with breast cancer
    • CALGB 9343 Study that compared two kinds of treatments for women who were at least 70 years old and had early (stage I) breast cancer that depended on the hormone called estrogen (called “ER positive” or “ER+”)
    • CALGB 9840 Study that compared timing and different ways to give treatment to patients whose breast cancer had spread to other parts of their body (called "metastatic")
    • CALGB 40101 Study that compared two different treatments for breast cancer patients who had no lymph nodes with cancer, or who had 1-3 lymph nodes with cancer. It also tested if 4 or 6 treatments worked better
    • CALGB 40302 Study that compared one drug to a combined treatment for women with advanced breast cancer that depends on a hormone called estrogen (ER positive or ER+)
    • CALGB 40502* Study that compared different drug treatments (chemotherapy) for adults with breast cancer that has returned or spread throughout the body (metastatic breast cancer)
    • CALGB 40503* Study that compared two different drug treatments in women beyond child-bearing age, with breast cancer that was hormone receptor-positive and had spread locally or to other areas of the body where surgery was no longer a treatment choice (advanced breast cancer)
    • CALGB 40601* Study that compared different drug treatments (chemotherapy) in patients with HER2 positive (HER2+) breast cancer that can be removed by surgery
    • CALGB 40603* Study that compared different drug treatments (chemotherapy) given before surgery for patients with triple-negative breast cancer, which is breast cancer without estrogen receptor (ER), progesterone receptor (PR) or HER2
    • CALGB 49907 Study that compared different chemotherapy (drug) treatments ways to treat older women with early breast cancer who are at least 65 years old; also other studies were included that examined quality of life for women on study and whether or not they took their medications as prescribed
    • CALGB 369901 Study that looked at whether survivorship care plans improved how women age 65 and over felt one year after finishing treatment for breast cancer
    • NCCTG N063D* Study that compared different drug treatments given after surgery for patients with HER2 positive breast cancer
    • NCCTG N9831 Study that compared different ways to give chemotherapy (drug) treatments to people with breast cancer that is called HER2/neu positive (HER2+)
    • NCCTG N10C2 Study compared magnesium oxide to placebo to see if it lowered hot flashes in breast cancer survivors who did not have monthly menstrual periods (menopausal)
  • Brain-related Cancers (including glioblastoma)
    • NCCTG N0574* Study that compared different radiation therapy treatments for patients with cancer that has spread to the brain
    • NCCTG N0776 Study that combined two drug treatments to treat people with brain tumors that have come back (a recurrence)
    • NCCTG N0779 Study that combined two drugs together to treat people with glioblastoma, a kind of brain tumor
    • NCCTG N09C6 Study that compared medicine mouth rinses for people who get radiotherapy to treat head and neck cancers and who developed mouth sores from their treatment
    • NCCTG N107C* Study that compared different types of radiation treatment given to patients after removing a metastatic brain tumor
  • Cancer of Unknown Primary
    • NCCTG N0871* Study that compared different drug treatments in patients with previously untreated cancer of unknown primary
  • Gastrointestinal - GI (including colon, esophageal and pancreatic cancers)
    • ACOSOG Z6051* Study that compared two types of surgery currently used in rectal cancer
    • Alliance A021101* Pilot study that compared different chemotherapy (drug) treatments before surgery for adults with pancreatic cancer
    • CALGB 80303 Pancreatic cancer study that compared two treatments for people whose cancer could not be removed by surgery
    • CALGB 80403* Study that compared different drug (chemotherapy) treatments for patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body
    • CALGB 80405* Study that compared different chemotherapy (drug) treatments for adults with colon or rectal cancer that has returned or spread throughout the body
    • CALGB 89803 Study that determined whether patients whose stage III colon cancer came back (called a “recurrence”) lived longer if they exercised after they received one of two different chemotherapy treatments
    • NCCTG N08CB Study that compared one dose to two doses of calcium and magnesium to a placebo (an inactive agent) for the prevention of a common side effect, called neuropathy (numbness and tingling), caused by the drug oxaliplatin, which is often used to treat patients with colon cancer
  • Genitourinary - GU (including bladder, kidney and prostate cancers)
    • Alliance A031203* Study that compared different drug treatments in patients with newly found kidney cancer that had spread from where it started to nearby tissue or to other places in the body
    • CALGB 70903 Study that reviewed a pain survey to see how it measured pain in men with a kind of prostate cancer that spread in their body (metastatic) and was called castrate-resistant
    • CALGB 90401 Study that compared cancer drug treatments after hormone treatment stopped working for men with prostate cancer that spread to other parts of their body (called metastatic)
  • Leukemia
    • CALGB 9011 Study that compared different chemotherapy (drug) treatments to see if a drug called “fludarabine” raised the number of patients with chronic lymphocytic leukemia (CLL) who get a second kind of cancer
    • CALGB 9720 Study in acute myeloid leukemia (AML) that compared different ways to give treatment to patients who were 60 years and older
    • CALGB 10001 Study that compared two kinds of stem cell transplants and a newer drug for people with Philadelphia-positive
      acute lymphoblastic leukemia (ALL) along with cancer drug treatment (chemotherapy)
    • CALGB 10503 Study that measured how age affects the time it takes for the drug busulfan to leave patients’ bodies when it is given as part of a stem cell transplant
    • CALGB 10603* Study that compared different chemotherapy treatment drugs in patients with leukemia cells with the abnormal FLT3 gene
  • Lymphoma
    • CALGB 50202 Study that looked at a new drug treatment (chemotherapy) for patients with newly diagnosed lymphoma in the central
      nervous system (CNS), which is commonly in the brain and spinal cord
    • CALGB 50401* Study that compared different drug (chemotherapy) treatments in patients with follicular non-Hodgkin lymphoma
    • CALGB 59804 A Hodgkin lymphoma study that examined a chemotherapy (drug) treatment to see if this treatment is effective and has tolerable side effects in patients whose disease had returned (called a “recurrence”) or had not responded to prior treatments (called “resistant”)
  • Melanoma
    • NCCTG N0775 Study that compared two different drug treatments for patients who have melanoma that has spread to other parts of the body (called “metastatic”) and cannot be removed with surgery
  • Multiple Myeloma
    • CALGB 100104 Study that compared a new drug treatment to no additional treatment for patients with multiple myeloma (a blood cancer) after they had a stem cell transplant
  • Respiratory (including lung and mesothelioma cancers)
    • CALGB 30402 Study that compared two new drugs given to patients whose cancer spread beyond the lungs (called metastatic)
    • CALGB 30607* Sttudy that determined how well a drug worked after treatment of chemotherapy in patients with stage IIIB-IV non-small cell lung cancer
    • CALGB 30801* Study that compared two treatments for patients with advanced non-small cell lung cancer
    • CALGB 31001 Study that compared different surgeries to remove lung cancer tumors to see which had better results for patients
    • CALGB 70601 Study that compared whether or not a patient's education made a difference in how long they lived
    • CALGB 70602 Study that compared the results of chemotherapy (drug) treatment based on where it was given to patients
    • NCCTG N0821 Study that measured a cancer treatment for patients with advanced non-small cell lung cancer who were at least 70 years old
  • Transplant
    • CALGB 10001 Study that compared two kinds of stem cell transplants and a newer drug for people with Philadelphia-positive
      acute lymphoblastic leukemia (ALL) along with cancer drug treatment (chemotherapy)

Rare tumors

  • Angiosarcoma (cancer of the inner lining of blood vessels)
    • Alliance A091102* Study that looked at how well a drug worked in treating patients with sarcoma that had spread to other places in the body and usually could no be cured or controlled with treatment or had spread to other places in the body
    • Alliance A091103* Study looked at a drug treatment for patients with a type of cancer called angiosarcoma that has spread through the body and could not be removed with surgery

Other conditions

  • Other Treatment Studies
    • CALGB 60301 Study that tried to find out a safe dose of sorafenib (a cancer drug which is also called Nexavar®) for patients with cancer whose liver or kidneys were not working properly
  • Managing Side Effects and Symptoms of Treatment
    • CALGB 70903 Study that reviewed a pain survey to see how it measured pain in men with a kind of prostate cancer that spread in their body (metastatic) and was called castrate-resistant
    • CALGB 170601 A phase III double blind trial of oral duloxetine for treatment of pain associated with chemotherapy-induced peripheral neuropathy (CIPN)
    • NCCTG N02C4* Study that looked at whether taking creatine supplement would increase weight and appetite in patients with weight loss caused by cancer
    • NCCTG N08CB Study that compared one dose to two doses of calcium and magnesium to a placebo (an inactive agent) for the prevention of a common side effect, called neuropathy (numbness and tingling), caused by the drug oxaliplatin, which is often used to treat patients with colon cancer
    • NCCTG N08C3 Study compared two treatments to lower the amount of nausea and vomiting (getting sick to the stomach) due to cancer treatment (chemotherapy)
    • NCCTG N0993 Study that compared three other studies that all used the same tools to measure skin rash symptoms in patients who received treatments like radiation or targeted therapies to see how the tools compared
    • NCCTG N10C2 Study that compared magnesium oxide to placebo to see if it lowered hot flashes in breast cancer survivors who did not have monthly menstrual periods (menopausal)
  • Improving How Care is Given
    • CALGB 70601 Lung cancer study that compared whether or not a patient's education made a difference in how long they lived
    • CALGB 70602 Lung cancer study that compared the results of chemotherapy (drug) treatment based on where it was given to patients
  • Determining Health Outcomes
    • CALGB 89803 Study that determined whether patients whose stage III colon cancer came back (called a “recurrence”) lived longer if they exercised after they received one of two different chemotherapy treatments
    • CALGB 369901 Study that looked at whether survivorship care plans improved how women age 65 and over felt one year after finishing treatment for breast cancer.

 

* denotes recently added summaries